



Additional information relating to Naturex and Natraceutical Group agreement

Avignon (FR) / Valencia (SP), 6 August 2009 - In the future, Natraceutical should hold between 38% and 40% of Naturex shares. The exact percentage will be adjusted over the next two months in result of the due diligence process.

Natraceutical will become a relevant minority shareholder and a board member of Naturex, chaired by Jacques Dikansky, Chairman and CEO.

According to the agreement signed yesterday between the two companies, SGD, the family controlled holding company of Jacques Dikansky will remain the reference shareholder of Naturex in terms of voting rights.

About Naturex

Naturex has a recognized place amongst the very top global leaders in natural extracts. Naturex manufactures and markets natural ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.

These products are exclusively sold to industrial companies. Today's market for extracts is very strong since the natural origin of ingredients fulfils a buoyant and fast-growing demand from end consumers. Naturex's strength lies in its ability to position itself on specific products which constitute market niches.

During the past ten years, Naturex has recorded a very strong growth. Revenues have been multiplied by ten during this period. To maintain the healthy organic growth of the group and to fully exploit the expertise in offering high value-added, high performance technical solutions for each of our different markets, Naturex has structured its activities, since 2009, into three core businesses: Food & Beverage, Nutrition & Health and Personal Care.

Based in Avignon, the group employs 600 staff and over 90% of its sales are overseas. Naturex has production units in France, Morocco, the United States and Italy, as well as 8 sales offices located in Europe, the USA and Asia.

Naturex quotes on NYSE Euronext Paris under the ticker FR0000054694; NRX. Total outstanding shares: 3,882,040. www.naturex.com

About Natraceutical Group

Spanish multinational corporation Natraceutical Group is at the forefront of biotechnology applied to nutrition, a leading reference in the research and development of naturally-sourced functional / active ingredients and nutritional complements for the foodstuffs, pharmaceutical and cosmetics sectors. The company streamlines its industrial activity through two divisions (Ingredients and Nutritional Supplements) with the purpose of contributing to the prevention of diseases and improving quality of life through nutrition.



The Group's Ingredients division currently runs production facilities in Spain, UK, Switzerland, Australia and Brazil; and operates actively in over 60 countries, running branches in Europe, US and the Asia Pacific region, plus several sales networks worldwide. Natraceutical provides products and services to over 1,000 companies worldwide, including eight of the world's ten leading food corporations.

In October 2006, Natraceutical expanded its sphere of activity by penetrating the nutritional supplements sector following the acquisition of Monaco-based company Laboratoires Forté Pharma, specializing in nutritional supplements for health, beauty and weight control, thanks to which the company gained direct access to end consumers.

Natraceutical quotes in the Spanish stock exchange under the ticker NATE.MC. Total outstanding shares: 328,713,946. www.natraceuticalgroup.com

Naturex contacts:	Natraceutical Group contact:	Actus contacts:
Jacques Dikansky, President and C.E.O. Phone: +33 (0)4 90 23 96 89 naturex@naturex.com Thierry Lambert, Vice-President and CFO Phone: +33 4 90 23 96 89 t.lambert@naturex.com	Gloria Folch Investor Relations and Communication Phone: +34 667 988 543 gloria.folch@natraceuticalgroup.com	Laurence Marquézy, Investor Relations Phone: +33 (0)1 72 74 82 23 lmarquezy@actus.fr Anne Catherine Bonjour, Press Relations Phone: + 33 (0)1 53 67 36 93 acbonjour@actus.fr